Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07568275 | Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance | EARLY_PHASE1 | ACTIVE NOT_RECRUITING | 30 | — | — | Nov 15, 2024 | Jan 1, 2028 | May 5, 2026 | 1 | United States |
Change in arterial elastance will be measure by echocardiography at baseline, 6 hours and 24 hours. Dynamic arterial elastance will be calculated as the ratio between pulse pressure variation and stroke volume variation obtained from arterial line waveform.
| Arm | Type | Description |
|---|---|---|
| Angiotensin II | ACTIVE_COMPARATOR | Angiotensin II will be continued for 24 hours and then discontinued, and SOC vasopressors resumed according to institutional practices. |
| Standard of Care | NO_INTERVENTION | Fixed-dose vasopressin and standard of care vasopressors increased as per institutional guidelines according to MAP targets. |
| Name | Type | Description |
|---|---|---|
| Giapreza | DRUG | 2.5 mg/mL |
Inclusion Criteria: * Age ≥ 18 years at the time of enrollment * Septic shock as defined by Sepsis-3 criteria (highly suspected or confirmed infection, requiring norepinephrine to maintain a MAP ≥ 65 mmHg, and serum lactate \> 2 mmol/L after adequate fluid resuscitation) within a 48 hour window pri...